|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Platelet biomarkers in Alzheimer's disease显示文摘The search for diagnostic and prognostic markers in Alzheimer's disease(AD) has been an area of active research in the last decades. Biochemical markers are correlates of intracerebral changes that can be identified in biological fluids, namely: peripheral blood(total blood, red and white blood cells, platelets, plasma and serum), saliva, urine and cerebrospinal fluid. An important feature of a biomarker is that it can be measured objectively and evaluated as(1) an indicator of disease mechanisms(markers of core pathogenic processes or the expression of downstream effects of these processes), or(2) biochemical responses to pharmacological or therapeutic intervention, which can be indicative of disease modification. Platelets have been used in neuropharmacological models since the mid-fifties, as they share several homeostatic functions with neurons, such as accumulation and release of neurotransmitters, responsiveness to variations in calcium concentration, and expression of membrane-bound compounds. Recent studies have shown that platelets also express several components related to the pathogenesis of AD,in particular to the amyloid cascade and the regulation of oxidative stress: thus they can be used in the search for biomarkers of the disease process. For instance, platelets are the most important source of circulating forms of the amyloid precursor protein and other important proteins such as Tau and glycogen synthase kinase-3B. Moreover, platelets express enzymes involved in membrane homeostasis(e.g., phospholipase A2), and markers of the inflammatory process and oxidative stress. In this review we summarize the available literature and discuss evidence concerning the potential use of platelet markers in AD. | Leda L Talib Helena PG Joaquim Orestes V Forlenza | 2012 | World Journal of Psychiatry2012，2，6： | 2 |
| 2 | Neurostructural predictors of Alzheimer's disease: a META-analysis of VBM studies显示文摘 | Ferreira LK Diniz BS Forlenza OV | 2011 | Neurobiol Aging2011，32，10： | 1 |
| 3 | Inhibition of phospho- lipase A2 reduces neurite outgrowth and neuronalviability显示文摘 | Forlenza OV Mendes CT Marie SK | 2007 | Prostaglandins Leukot Essent Fatty Acids2007，76，1： | 1 |
| 4 | Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer' s disease ? A systematic review and meta-a- nalysis of the literature 显示文摘 | Diniz BS Pinto JJ Forlenza OV | 2008 | World J Biol Psychiatry2008，9，3： | 1 |
| 5 | Diagnostic transitions in mild cognitive impairment subtypes显示文摘 | Forlenza OV Diniz BS Nunes PV | 2009 | Int Psychogeriatr2009，21，： | 1 |
| 6 | Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder 显示文摘 | Nunes P V Forlenza O V Gattaz W F | 2007 | Br J Psychiatry2007，190，： | 1 |
| 7 | Neurostruc- rural predictors of Alzheimer's disease: a meta-analysis of VBM studies显示文摘 | Ferreira LK Diniz BS Forlenza OV | 2011 | Neurobiol Aging2011，32，10： | 1 |
| 8 | Disease -modifying properties of long - term lithium treatment for anmestic mild cognitive impairment: randomised controlled trial 显示文摘 | Forlenza OV Diniz BS Radanovic M | 2011 | Br J Psychiatry2011，198，5： | 1 |
| 9 | Do CSF total tau, phosphorylated tau, and beta - amyloid 42 help top redict progression of mild cognitive impairment to Alzheimerps disease? A systematic review and meta - analysis of the literature显示文摘 | DinizBS Pinto JA J r Forlenza OV | 2008 | World J Biol Psychiatry2008，9，3： | 1 |
| 10 | Muscarinic agonists reduce tau phosph- orylation in non-neuronal cells via GSK-3beta inhibition and in neurons显示文摘 | Forlenza 0 V Spink J M Dayanandan R | 2000 | J Neural Transm2000，107，10： | 1 |
| 11 | Disease-modifying proper- ties of long-term lithium treatment for amnestic mild cognitive im- paimlent :randomised controlled trial 显示文摘 | Forlenza OV Diniz BS Anovic M | 2011 | Br J Psychiatry2011，198，5： | 1 |
| 12 | Depression and oxidative damage to lipids 显示文摘 | SARAH Y MICHAEL J FORLENZA etal | 2010 | Psychoneuroendocrinology2010，35，： | 1 |
| 13 | Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease显示文摘 | Schaeffer EL Forlenza OV Gattaz WF | 2009 | Psychopharmacology (Bed)2009，202，13： | 1 |
| 14 | Do CSF total tau,phosphorylated tau,and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer' s disease? A systematic review and meta-analysis of the literature显示文摘 | Diniz BS Pinto Junior JA Forlenza OV | | 0，，03： | 1 |
| 15 | Diagnosis and biomarkers of predementia in Alzheimefs disease显示文摘 | Forlenza O V Diniz B S Gattaz W F | 2010 | BMC Med2010，8，： | 1 |
| 16 | Myeloablative chemo- therapy with autologous stem cell transplant for desmoplastic small round cell tumor显示文摘 | Forlenza C J Kushner BH Kernan N | 2015 | Sarcoma2015，2015，26： | 1 |
| 17 | Diagnosis and biomarkers of predementia in Alzheimer’s disease显示文摘 | Forlenza OV Diniz BS Gattaz WF | 2010 | BMC Med2010，8，1： | 1 |
| 18 | Diagnosis and biomarkers of predementia in Alzheimer's disease显示文摘 | Forlenza O V Diniz B S Gattaz W F | 2010 | BMC Med2010，8，： | 1 |
| 19 | Disease-modifying properties of long-term lithiumtreatment for amnestic mild cognitive impairment:randomised controlled trial显示文摘 | Forlenza OV Diniz BS Radanovic M | 2011 | Br J Psychiatry2011，198，： | 1 |
| 20 | Effect of brain-derived neurotrophie factor Va166Met polymorphism and serum levels on the progression of mild cognitive impairment显示文摘 | Forlenza OV Diniz BS Teixeira AL | 2010 | World J Biol Psychiatry2010，11，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员